Abstract

PurposeAn antibubble is an encapsulated gas bubble with an incompressible inclusion inside the gas phase. Current‐generation ultrasound contrast agents are bubble‐based: they contain encapsulated gas bubbles with no inclusions. The objective of this work is to determine the linear and nonlinear responses of an antibubble contrast agent in comparison to two bubble‐based ultrasound contrast agents, that is, reference bubbles and SonoVueTM.MethodsSide scatter and attenuation of the three contrast agents were measured, using single‐element ultrasound transducers, operating at 1.0, 2.25, and 3.5 MHz. The scatter measurements were performed at acoustic pressures of 200 and 300 kPa for 1.0 MHz, 300 kPa, and 450 kPa for 2.25 MHz, and 370 and 560 kPa for 3.5 MHz. Attenuation measurements were conducted at pressures of 13, 55, and 50 kPa for 1.0, 2.25, and 3.5 MHz, respectively. In addition, a dynamic contrast‐enhanced ultrasound measurement was performed, imaging the contrast agent flow through a vascular phantom with a commercial diagnostic linear array probe.ResultsAntibubbles generated equivalent or stronger harmonic signal, compared to bubble‐based ultrasound contrast agents. The second harmonic side‐scatter amplitude of the antibubble agent was up to 3 dB greater than that of reference bubble agent and up to 4 dB greater than that of SonoVueTM at the estimated concentration of 8×104 bubbles/mL. For ultrasound with a center transmit frequency of 1.0 MHz, the attenuation coefficient of the antibubble agent was 8.7 dB/cm, whereas the attenuation coefficient of the reference agent was 7.7 and 0.3 dB/cm for SonoVueTM. At 2.25 MHz, the attenuation coefficients were 9.7, 3.0, and 0.6 dB/cm, respectively. For 3.5 MHz, they were 4.4, 1.8, and 1.0 dB/cm, respectively. A dynamic contrast‐enhanced ultrasound recording showed the nonlinear signal of the antibubble agent to be 31% greater than for reference bubbles and 23% lower than SonoVueTM at a high concentration of 2×106 bubbles/mL.ConclusionEndoskeletal antibubbles generate comparable or greater higher harmonics than reference bubbles and SonoVueTM. As a result, antibubbles with liquid therapeutic agents inside the gas phase have high potential to become a traceable therapeutic agent.

Highlights

  • Ultrasound contrast agents (UCAs) are utilized in the clinic to visualize the blood pool and assess organ perfusion and dispersion, aiding cancer detection.[1,2,3,4] In some cases, the current UCAs do not exhibit sufficient nonlinear behavior to eliminate clutter and image artifacts, leading to diagnostic misinterpretation.[5]

  • Theoretical analysis predicts that all the harmonic amplitudes scattered by a UCA dispersion are proportional to the bubble concentration, in the low concentration range, and the bubble radius.[11,39,42]

  • This opens the door to improving contrastenhanced ultrasound (CE-US) image quality and to a traceable therapeutic agent with large amounts of therapeutic compounds in the core

Read more

Summary

Introduction

Ultrasound contrast agents (UCAs) are utilized in the clinic to visualize the blood pool and assess organ perfusion and dispersion, aiding cancer detection.[1,2,3,4] In some cases, the current UCAs do not exhibit sufficient nonlinear behavior to eliminate clutter and image artifacts, leading to diagnostic misinterpretation.[5] Augmenting UCA nonlinear behavior improves image contrast and diagnostic confidence. To this end, we propose antibubbles as a new UCA. We investigate the possibility of using a contrast agent with augmented nonlinear behavior for this purpose, enabling imaging at lower pressure amplitudes and causing weaker higher harmonic generation in tissue

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call